Akademik Veri Yönetim Sistemi
6th European Congress of Immunology , 1 - 04 Eylül 2021, ss.113
HLA plays a pivotal role in the immune response to pathogens so HLA variation may be associated with SARS‐COV‐2 infection. We aimed to assess the association between HLA allele
frequency distribution in a group of 72 patients affected by mild and moderate/severe form of COVID‐19. HLA‐A, ‐B, ‐DRB1 typing in 72 COVID‐19 patients (males/females: 41/31)
and 300 healthy controls by using Sequence‐Specific Oligonucleotide (SSO) method were performed. Patients were divided into two groups: Moderate/Severity Group (n=48,
males/females: 29/19) included patients who were required hospital care and mild group (n=24, males/females: 12/12) patients who did not have any symptoms or presented with
mild disease. The most common antigens in patients with mild symptoms (MS) and healthy controls (HC) were HLA‐A*02 (MS: 35.4% ‐ HC: 25,3%), ‐B*35 (MS: 14.6% ‐HC: 17,2%),
‐DRB1*04 (MS: 14.6% ‐ HC: 17,2) while in the patients with moderate/severe symptoms were HLA‐A*02 (30.2%), ‐B*35 (18,8%) and DRB1*07 (20.8%). Compared to healthy subjects,
there was a decrease in HLA‐DRB1*04 (p=0,028) allele, however increase in HLA‐B*50 (p=0,004) and DRB1*07 (p=0,012) alleles in COVID‐19 patients. Also, higher rate of the alleles
HLA‐A*33 (p=0,042), HLA‐B*44 (p=0,003), HLA‐B*57 (p=0,035) in mild group than in moderate/severe group while higher rate of the allele HLA‐B*50 (p=0,009) in moderate/severe
group was compared to mild group. Our findings suggest that HLA‐DRB1*07 and HLA‐B*50 may be associated with COVID‐19 disease susceptibility, HLA‐B*50 with severe infection,
and also HLA‐A*33, ‐B*44, ‐B*57, ‐DRB1*04 may be protective against the COVID‐19 disease as well.